Linked Life Data

17392405

Source:http://linkedlifedata.com/resource/pubmed/id/17392405

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17392405rdf:typepubmed:Citationlld:pubmed
pubmed-article:17392405lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:17392405lifeskim:mentionsumls-concept:C1421429lld:lifeskim
pubmed-article:17392405lifeskim:mentionsumls-concept:C1421467lld:lifeskim
pubmed-article:17392405lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:17392405lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:17392405lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:17392405lifeskim:mentionsumls-concept:C1744311lld:lifeskim
pubmed-article:17392405lifeskim:mentionsumls-concept:C1519952lld:lifeskim
pubmed-article:17392405pubmed:issue3lld:pubmed
pubmed-article:17392405pubmed:dateCreated2007-5-15lld:pubmed
pubmed-article:17392405pubmed:abstractTextVanilloid receptor-1 (TRPV1) is a nonselective cation channel, predominantly expressed by sensory neurons, which plays a key role in the detection of noxious painful stimuli such as capsaicin, acid, and heat. TRPV1 antagonists may represent novel therapeutic agents for the treatment of a range of conditions including chronic pain, migraine, and gastrointestinal disorders. Here we describe the in vitro pharmacology of N-(2-bromophenyl)-N'-[((R)-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)]urea (SB-705498), a novel TRPV1 antagonist identified by lead optimization of N-(2-bromophenyl)-N'-[2-[ethyl(3-methylphenyl)amino]ethyl]urea (SB-452533), which has now entered clinical trials. Using a Ca(2+)-based fluorometric imaging plate reader (FLIPR) assay, SB-705498 was shown to be a potent competitive antagonist of the capsaicin-mediated activation of the human TRPV1 receptor (pK(i) = 7.6) with activity at rat (pK(i) = 7.5) and guinea pig (pK(i) = 7.3) orthologs. Whole-cell patch-clamp electrophysiology was used to confirm and extend these findings, demonstrating that SB-705498 can potently inhibit the multiple modes of receptor activation that may be relevant to the pathophysiological role of TRPV1 in vivo: SB-705498 caused rapid and reversible inhibition of the capsaicin (IC(50) = 3 nM)-, acid (pH 5.3)-, or heat (50 degrees C; IC(50) = 6 nM)-mediated activation of human TRPV1 (at -70 mV). Interestingly, SB-705498 also showed a degree of voltage dependence, suggesting an effective enhancement of antagonist action at negative potentials such as those that might be encountered in neurons in vivo. The selectivity of SB-705498 was defined by broad receptor profiling and other cellular assays in which it showed little or no activity versus a wide range of ion channels, receptors, and enzymes. SB-705498 therefore represents a potent and selective multimodal TRPV1 antagonist, a pharmacological profile that has contributed to its definition as a suitable drug candidate for clinical development.lld:pubmed
pubmed-article:17392405pubmed:languageenglld:pubmed
pubmed-article:17392405pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17392405pubmed:citationSubsetIMlld:pubmed
pubmed-article:17392405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17392405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17392405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17392405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17392405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17392405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17392405pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17392405pubmed:statusMEDLINElld:pubmed
pubmed-article:17392405pubmed:monthJunlld:pubmed
pubmed-article:17392405pubmed:issn0022-3565lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:DavisJohn BJBlld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:SmartDarrenDlld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:SmithGraham...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:GunthorpeMart...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:RandallAndrew...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:JermanJeffrey...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:EgertonJulieJlld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:WrightJimJlld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:ThompsonMervy...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:RamiHarshad...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:BroughStephen...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:HollandVicky...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:WinbornKimKlld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:LappinSarah...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:HannanSara...lld:pubmed
pubmed-article:17392405pubmed:authorpubmed-author:ArpinoSandraSlld:pubmed
pubmed-article:17392405pubmed:issnTypePrintlld:pubmed
pubmed-article:17392405pubmed:volume321lld:pubmed
pubmed-article:17392405pubmed:ownerNLMlld:pubmed
pubmed-article:17392405pubmed:authorsCompleteYlld:pubmed
pubmed-article:17392405pubmed:pagination1183-92lld:pubmed
pubmed-article:17392405pubmed:dateRevised2011-2-1lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:meshHeadingpubmed-meshheading:17392405...lld:pubmed
pubmed-article:17392405pubmed:year2007lld:pubmed
pubmed-article:17392405pubmed:articleTitleCharacterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.lld:pubmed
pubmed-article:17392405pubmed:affiliationNeurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, UK. martin_j_gunthorpe@gsk.comlld:pubmed
pubmed-article:17392405pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17392405lld:pubmed